你的上述行为违反了《上市公司股东、董监高减持股份的若干规定》(证监会公告〔2017〕9号)第十一条第 一款及《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》(深证上〔2017〕820 号)第五条第二款规定。根据《上市公司股东、董监高减持股份的若干规定》(证监会公告〔2017〕9号)第十四条 的规定,我局决定对你采取出具警示函的监管措施,并记入证券期货市场诚信档案。你应充分吸取教训,加强对证券 法律法规的学习,严格规范减持上市公司股份的行为,杜绝此类事件再次发生。你应在收到本决定书的10个工作日 内向我局提交书面报告。 严琳: 经查,2021年11月30日,你通过大宗交易买入雅本化学股份有限公司(以下简称雅本化学)实际控制人之一、持 股5%以上股东汪新芽所持雅本化学股份1900万股,占总股本的1.97%。前述股份转让前,汪新芽持有雅本化学股份 8400.04万股,其中8164.30万股系通过协议受让新余科盈投资管理有限公司持有的首次公开发行前股份并经两次转 增形成。你在受让汪新芽所持雅本化学股份后,于2021年12月1日通过集中竞价交易将受让股份全部减持。 | 索 | 引 | 号 | b ...

(一)本次诉讼的前期披露情况 1、鉴于公司涉及证券虚假陈述责任纠纷案件未达到重大诉讼的相关信息披 露标准，公司在定期报告中对案件的基本信息进行列示。详见公司于2022年8月 26日在指定信息披露网站巨潮资讯网（www.cninfo.com.cn）披露的《雅本化学 股份有限公司2022年半年度报告》。 证券代码：300261 证券简称：雅本化学 公告编号：2023-046 雅本化学股份有限公司 关于民事诉讼的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 2023 年 4 月 29 日，雅本化学股份有限公司（以下简称"公司"）在指定信 息披露网站巨潮资讯网（www.cninfo.com.cn）披露了《关于收到民事判决书暨 诉讼进展公告》（公告编号：2023-026），公司所涉证券虚假陈述责任纠纷案件 共立案 48 件均已作出一审判决，收到送达的全部一审判决书共计 35 份（部分案 件合并判决），需承担的赔偿损失合计金额为 2,593,035.33 元（不包括案件受理 费）。公司对上述一审判决结果提起了上诉。 近日，公司陆续收到江苏省高级人民法院送达的（20 ...

Financial Performance - The company reported a total revenue of RMB 954,685,571 for the year 2022, with a cash dividend of RMB 0.5 per 10 shares to all shareholders[5]. - The company's operating revenue for 2022 was CNY 2,000,975,899.68, a decrease of 3.42% compared to CNY 2,071,740,062.67 in 2021[22]. - Net profit attributable to shareholders increased by 11.60% to CNY 202,948,039.69 from CNY 181,849,264.51 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 54.30% to CNY 225,892,277.97, compared to CNY 146,401,786.78 in 2021[22]. - The total revenue for the reporting period was CNY 2,000.98 million, a decrease of 3.42% compared to the previous year[47]. - The net profit attributable to shareholders of the listed company was CNY 202.95 million, an increase of 11.60% year-on-year[47]. Market and Product Development - The company plans to expand its market presence and enhance its product offerings through new product development and technological advancements[5]. - The company focuses on providing CDMO services for multinational pesticide and pharmaceutical companies, emphasizing process development and optimization for key intermediates[35]. - The company is actively engaged in contract development and manufacturing (CDMO) services, catering to the pharmaceutical sector[15]. - The company has a designed capacity of 9,320 tons for pesticide intermediates and active ingredients, with a utilization rate of 66.58%[39]. - The company is currently constructing additional capacity of 700 tons for pesticide intermediates and 290 tons for pharmaceutical intermediates[39]. Research and Development - The company has invested significantly in R&D, leading to the successful commercialization of several patented products[41]. - The company’s R&D investment ratio is among the top in the industry, enhancing its competitive edge in various technical fields[45]. - The company is focused on expanding its product registration portfolio, with several products having registration validity extending into 2028, such as 95% Thiamethoxam and 98% Flupyradifurone[43]. - The company is committed to developing low-toxicity pesticides, with products like 98.5% Fluoropyrimidine and 95% Fluorosilicon showing significant efficacy against various pests[42]. Governance and Compliance - The company has established a robust governance structure, with all board members present for the report's approval[5]. - The company emphasizes its commitment to maintaining the accuracy and completeness of its financial reports, ensuring transparency for investors[5]. - The company has a governance structure in place with independent directors and a clear separation of roles among board members[133]. - The company has maintained compliance with relevant laws and regulations, ensuring that all shareholders, especially minority shareholders, can exercise their rights[125]. Environmental Responsibility - The company is committed to environmental and social responsibility, as outlined in its annual report[5]. - The company adheres to various environmental protection laws and regulations, ensuring compliance in its production processes[165]. - The company has obtained pollution discharge permits valid until December 2025 and November 2027 for its subsidiaries, demonstrating commitment to environmental standards[166]. - The company has implemented continuous monitoring of emissions, ensuring compliance with air quality standards[173]. Risk Management - The company has identified potential risks that could impact its operations and has outlined corresponding countermeasures in its management discussion[5]. - The company faces risks from macroeconomic fluctuations and stringent environmental policies, which may impact financial performance[119]. - To mitigate risks, the company will enhance its risk management capabilities and invest in environmental compliance measures[120]. Shareholder Engagement - The company conducted three temporary shareholder meetings and one annual shareholder meeting in 2022, with investor participation rates of approximately 29%[130]. - The company has a commitment to transparency in its reporting and governance practices, as evidenced by the detailed disclosures in its annual report[134]. - The company reported a cash dividend of RMB 0.5 per 10 shares, totaling RMB 47,734,278.55, which accounted for 100% of the profit distribution[156]. Strategic Partnerships and Acquisitions - The company is exploring potential acquisitions to enhance its product portfolio and market presence, targeting companies with complementary technologies[139]. - A new strategic partnership has been established with a leading technology firm to co-develop innovative solutions, expected to launch by mid-2024[139]. Employee Management - The total number of employees at the end of the reporting period was 1,038, with 191 in the parent company and 847 in major subsidiaries[151]. - The company has a performance-oriented salary management system to enhance employee motivation and align with market standards[153]. - The company emphasizes continuous employee training to improve professional skills and management capabilities[154].

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230717 | --- | --- | |-----------------|------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活动 | ☑ 特定对象调研□分析师会议 | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会□路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 | 长江证券 王明 | | 人员姓名 | 人保资产 肖迪 | | 时间 | 2023 年 7 月 17 日 ( 周一 ) 15:00~16:00 | | 地点 | 普陀区宁夏路 201 号 24 楼会议室 | | 上市公司接待人 | 副总经理、董事会秘书王一川先生 | | 员姓名 | | | | 一、董事会秘书王一川先生介绍了雅本化学股份有限公司整体 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230712 投资者关系活动 ☑特定对象调研□分析师会议 类别 □媒体采访□业绩说明会 □新闻发布会□路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 中信建投证券 郭祝同 时间 2023 年 7 月 12 日 (周三) 15:00~17:00 地点 雅本张江创新中心会议室 上市公司接待人 1、副总经理、董事会秘书王一川先生 员姓名 2、监事、研发总监阙利民先生 一、董事会秘书王一川先生介绍了雅本化学股份有限公司整体 的基本情况，包括主营业务、研发中心及生产基地布局，以及未 来发展规划；研发总监阙利民先生介绍了公司医药中间体、生物 酶及合成生物学等业务的发展情况。 二、互动交流情况： 1、康宽中间体 2022 年的营收是多少？公司如何应对专利期内产 投资者关系活动 品过专利期后的市场竞争？ 主要内容介绍 答：公司生产的康宽中间体，又称为氯虫苯甲酰胺高级中间体， 1) 2022 年度销售额为 9.79 亿元，是公司农药业务的重要组成部分， 并且与客户签署了长期合作协议。公司该产品的商业 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230705 投资者关系活动 ☑特定对象调研□分析师会议 类别 □媒体采访□业绩说明会 □新闻发布会□路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 兴证全球基金： 陈锦泉、孙若炜、李楠竹、谢长雁 时间 2023 年 7 月 5 日 (周三) 10:00~11:30 地点 兴证全球基金会议室 上市公司接待人 1、董事长、总经理蔡彤 员姓名 2、副总经理、董事会秘书王一川 一、董事会秘书王一川先生介绍雅本化学股份有限公司整体的 基本情况，公司业务布局以及未来发展规划。 公司主要从事植物保护产品、医药中间体及营养保健品的研 发和生产，目前拥有八大生产基地及三大研发中心。 早期生产基地位于江苏太仓，随后陆续投资建设南通如东基 地，并购盐城滨海基地，布局欧洲马耳他基地，建成浙江上虞基 地，通过产业基金合作建立湖北襄阳基地、辽宁阜新基地，最新 投资者关系活动 投资甘肃兰州基地。 主要内容介绍 公司目前已形成以上海张江创新中心、朴颐化学、颐辉生物 为核心的三大研发中心，并与复旦大学、上海交通大 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230703 | --- | --- | |-----------------------------|--------------------------------------------------------------| | | | | 投资者关系活动 | 特定对象调研□分析师会议 | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会□路演活动 | | | 现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 | 沃胜私募基金 魏延军 | | 人员姓名 | 中域资产 袁鹏涛 | | | 东吴证券 陈淑娴、周少玟 | | | 广发基金 王云骢 | | | 广发证券 张慧、曲尚浩 | | | 东北证券 喻杰 | | 时间 | 2023 年 7 月 3 日 ( 周一 ) 9:00~17:00 | | 地点 | 雅本张江创新中心 | | | 南通雅本化学有限公司 | | | | | 上市公司接待人 | 、董事长、总经理蔡彤 | | 员姓名 | 、董事、副总经理毛海峰 | | ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230517 | --- | --- | --- | |-------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称及 人员姓名 | 东吴证券：陈淑娴、何亦桢 | | | 时间 | 2023 年 5 月 17 日 | 9:30 | | 地点 | 南通雅本化学办公室 | | | 上市公司接待人 | 王一川 陈海华 南通雅本常务副 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20230516 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ☑业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 16 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理蔡彤 | | 员姓名 | 2、财务总监王爱军 | | | 3、副总经理、董事会秘书王一川 | | | 4、独立董事饶艳超 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、能预测一下今年全年的利润有多少与 2022 年比是增加还 | | | 是减少。公司有几个生产 ...

Financial Performance - The company's operating revenue for 2022 was ¥2,000,975,899.68, a decrease of 3.42% compared to ¥2,071,740,062.67 in 2021[22]. - Net profit attributable to shareholders increased by 11.60% to ¥202,948,039.69 in 2022 from ¥181,849,264.51 in 2021[22]. - The net profit after deducting non-recurring gains and losses rose by 54.30% to ¥225,892,277.97 in 2022 compared to ¥146,401,786.78 in 2021[22]. - Total assets at the end of 2022 were ¥4,008,418,399.76, reflecting a 5.32% increase from ¥3,806,025,067.11 at the end of 2021[22]. - The company's net assets attributable to shareholders increased by 9.80% to ¥2,387,566,980.33 at the end of 2022 from ¥2,174,390,029.16 at the end of 2021[22]. - The total revenue for the year 2022 was CNY 2,000.98 million, a decrease of 3.42% compared to the previous year[46]. - The net profit attributable to shareholders was CNY 202.95 million, an increase of 11.60% year-on-year[46]. - Revenue from the chemical industry was approximately $1.84 billion, accounting for 91.83% of total revenue, down 4.82% year-over-year[50]. - Revenue from the environmental protection industry increased by 15.75% to approximately $163.40 million, representing 8.17% of total revenue[50]. - Sales of pesticide intermediates decreased by 15.72% to approximately $1.20 billion, accounting for 60.06% of total revenue[50]. - Sales of pharmaceutical intermediates increased by 30.07% to approximately $441.62 million, representing 22.07% of total revenue[50]. Cash Flow and Investments - The net cash flow from operating activities significantly decreased by 80.82% to ¥81,067,227.82 in 2022 from ¥422,704,008.77 in 2021[22]. - The company reported a significant decline in cash flow from operations in Q1 2022, with a net cash flow of -¥108,978,197.34[24]. - Operating cash inflow decreased by 20.07% to ¥1,744,731,071.50, primarily due to a 20.73% drop in cash received from sales[67]. - The net increase in cash and cash equivalents was a decrease of 477.53%, resulting in a net decrease of ¥134,888,263.18[68]. - The total investment amount for the reporting period was 17 million yuan, representing a 70% increase compared to 10 million yuan in the same period last year[77]. - The company made significant equity investments, including a 100% stake in Lanzhou Yaben Chemical Co., with an investment amount of 7,000,000 CNY[78]. - The total amount of foreign exchange contracts at the end of the reporting period was 35,774.26 million CNY, representing 0.85% of the company's net assets[82]. - The company has established a derivative investment management system to mitigate risks associated with foreign exchange fluctuations[83]. Research and Development - The company has invested significantly in R&D, leading to optimized processes and a strong competitive position in the market[40]. - The company’s R&D investment ratio is among the top in the industry, focusing on innovative pesticides and pharmaceuticals[44]. - The company is focusing on enhancing its R&D capabilities and expanding its market presence through strategic project adjustments[94]. - Continuous investment in R&D is planned, with a focus on synthetic biology and green chemistry to enhance the company's competitive edge[111]. - The company is actively expanding its product offerings in the fields of anti-tumor and anti-pathogen areas through strategic R&D initiatives[37]. Market Position and Strategy - The company is positioned to benefit from the ongoing consolidation in the pesticide industry, with a focus on environmentally friendly products[33]. - The company has a market share of 50-60% for its bromoxynil products, which are recognized as high-efficiency and environmentally friendly pesticides[40]. - The company aims to expand its market reach through new product registrations and maintaining compliance with regulatory standards[42]. - The company plans to delay the new production line project in Nantong to July 2023, and the enzyme preparation and green research institute projects to May 2023[94]. - The company plans to use the remaining funds from terminated projects for the enzyme preparation and green research institute project[97]. Environmental Compliance - The company adheres to various environmental protection laws and regulations, ensuring compliance in its production processes[161]. - The company has obtained pollution discharge permits valid until December 2025 and November 2027 for its subsidiaries[162]. - The company has implemented comprehensive waste treatment facilities to minimize environmental impact[161]. - The company reported a total wastewater discharge of 15.847 tons per year, with a COD concentration of 70 mg/L, exceeding the regulatory limit[163]. - The company has established a monitoring system for wastewater discharge to ensure it remains within regulatory limits[165]. Corporate Governance - The company has a governance structure in place with a clear distinction of roles among directors and management[128]. - The company appointed a new deputy general manager and board secretary, Wang Yichuan, on December 19, 2022[129]. - The company has a structured approach to board member appointments and departures, ensuring continuity in governance[129]. - The company reported a total shareholding of 271.0 million shares, with no changes in the number of shares held by directors and supervisors during the reporting period[128]. - The company has not reported any changes in the voting rights of preferred shareholders[127]. Employee Management - The total number of employees at the end of the reporting period was 1,038, with 191 in the parent company and 847 in major subsidiaries[146]. - The employee training program includes both internal and external training to enhance professional skills and management levels, aligning with the company's sustainable development needs[149]. - The company has a performance-oriented compensation management system to motivate employees and attract talent, considering industry salary levels and overall company performance[148]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 5.5465 million yuan[136]. Risk Management - The company faces risks from macroeconomic fluctuations and stringent environmental regulations, which may impact financial performance[114]. - To mitigate risks, the company will enhance its operational resilience and invest in environmental compliance measures[115]. - The company faces potential negative impacts on gross margin and profitability due to fluctuations in raw material prices, which are influenced by market supply and demand[116]. - The company is enhancing its cost management system and exploring new procurement models to ensure supply chain stability and optimize procurement costs[116]. Legal and Regulatory Matters - The company is involved in a legal case with a claim amount of 4.4865 million yuan related to securities false statements, which is expected to have no significant impact on its performance[198]. - The company faced disciplinary actions for violations of the Shenzhen Stock Exchange listing rules, resulting in public reprimands for multiple executives[200]. - The violations included breaches of specific articles in the revised listing rules effective December 2020[200].